25 results on '"Anyaegbu, Chidozie C."'
Search Results
2. TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut
- Author
-
Gorecki, Anastazja M., Anyaegbu, Chidozie C., and Anderton, Ryan S.
- Published
- 2021
- Full Text
- View/download PDF
3. Secondary Degeneration Impairs Myelin Ultrastructural Development in Adulthood following Adolescent Neurotrauma in the Rat Optic Nerve.
- Author
-
Lins, Brittney R., Anyaegbu, Chidozie C., McGonigle, Terence, Hellewell, Sarah C., Patel, Parth, Reagan, Harry, Rooke-Wiesner, Cara, Warnock, Andrew, Archer, Michael, Hemmi, Jan M., Bartlett, Carole, and Fitzgerald, Melinda
- Subjects
- *
ADOLESCENCE , *MYELIN , *OPTIC nerve , *ADULTS , *WHITE matter (Nerve tissue) , *NERVOUS system injuries , *MYELIN proteins - Abstract
Adolescence is a critical period of postnatal development characterized by social, emotional, and cognitive changes. These changes are increasingly understood to depend on white matter development. White matter is highly vulnerable to the effects of injury, including secondary degeneration in regions adjacent to the primary injury site which alters the myelin ultrastructure. However, the impact of such alterations on adolescent white matter maturation is yet to be investigated. To address this, female piebald-virol-glaxo rats underwent partial transection of the optic nerve during early adolescence (postnatal day (PND) 56) with tissue collection two weeks (PND 70) or three months later (PND 140). Axons and myelin in the transmission electron micrographs of tissue adjacent to the injury were classified and measured based on the appearance of the myelin laminae. Injury in adolescence impaired the myelin structure in adulthood, resulting in a lower percentage of axons with compact myelin and a higher percentage of axons with severe myelin decompaction. Myelin thickness did not increase as expected into adulthood after injury and the relationship between the axon diameter and myelin thickness in adulthood was altered. Notably, dysmyelination was not observed 2 weeks postinjury. In conclusion, injury in adolescence altered the developmental trajectory, resulting in impaired myelin maturation when assessed at the ultrastructural level in adulthood. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Secondary Degeneration of Oligodendrocyte Precursor Cells Occurs as Early as 24 h after Optic Nerve Injury in Rats.
- Author
-
Toomey, Lillian M., Papini, Melissa G., Clarke, Thomas O., Wright, Alexander J., Denham, Eleanor, Warnock, Andrew, McGonigle, Terry, Bartlett, Carole A., Fitzgerald, Melinda, and Anyaegbu, Chidozie C.
- Subjects
OPTIC nerve injuries ,DNA ,BLOOD-brain barrier ,OPTIC nerve ,OXIDATIVE stress - Abstract
Optic nerve injury causes secondary degeneration, a sequela that spreads damage from the primary injury to adjacent tissue, through mechanisms such as oxidative stress, apoptosis, and blood-brain barrier (BBB) dysfunction. Oligodendrocyte precursor cells (OPCs), a key component of the BBB and oligodendrogenesis, are vulnerable to oxidative deoxyribonucleic acid (DNA) damage by 3 days post-injury. However, it is unclear whether oxidative damage in OPCs occurs earlier at 1 day post-injury, or whether a critical 'window-of-opportunity' exists for therapeutic intervention. Here, a partial optic nerve transection rat model of secondary degeneration was used with immunohistochemistry to assess BBB dysfunction, oxidative stress, and proliferation in OPCs vulnerable to secondary degeneration. At 1 day post-injury, BBB breach and oxidative DNA damage were observed, alongside increased density of DNA-damaged proliferating cells. DNA-damaged cells underwent apoptosis (cleaved caspase3+), and apoptosis was associated with BBB breach. OPCs experienced DNA damage and apoptosis and were the major proliferating cell type with DNA damage. However, the majority of caspase3+ cells were not OPCs. These results provide novel insights into acute secondary degeneration mechanisms in the optic nerve, highlighting the need to consider early oxidative damage to OPCs in therapeutic efforts to limit degeneration following optic nerve injury. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Plasma Lipid Profiles Change with Increasing Numbers of Mild Traumatic Brain Injuries in Rats.
- Author
-
Anyaegbu, Chidozie C., Szemray, Harrison, Hellewell, Sarah C., Lawler, Nathan G., Leggett, Kerry, Bartlett, Carole, Lins, Brittney, McGonigle, Terence, Papini, Melissa, Anderton, Ryan S., Whiley, Luke, and Fitzgerald, Melinda
- Subjects
BRAIN injuries ,BLOOD lipids ,CHOLINE ,LIQUID chromatography-mass spectrometry ,FREE fatty acids ,BLOOD-brain barrier - Abstract
Mild traumatic brain injury (mTBI) causes structural, cellular and biochemical alterations which are difficult to detect in the brain and may persist chronically following single or repeated injury. Lipids are abundant in the brain and readily cross the blood-brain barrier, suggesting that lipidomic analysis of blood samples may provide valuable insight into the neuropathological state. This study used liquid chromatography-mass spectrometry (LC-MS) to examine plasma lipid concentrations at 11 days following sham (no injury), one (1×) or two (2×) mTBI in rats. Eighteen lipid species were identified that distinguished between sham, 1× and 2× mTBI. Three distinct patterns were found: (1) lipids that were altered significantly in concentration after either 1× or 2× F mTBI: cholesterol ester CE (14:0) (increased), phosphoserine PS (14:0/18:2) and hexosylceramide HCER (d18:0/26:0) (decreased), phosphoinositol PI(16:0/18:2) (increased with 1×, decreased with 2× mTBI); (2) lipids that were altered in response to 1× mTBI only: free fatty acid FFA (18:3 and 20:3) (increased); (3) lipids that were altered in response to 2× mTBI only: HCER (22:0), phosphoethanolamine PE (P-18:1/20:4 and P-18:0/20:1) (increased), lysophosphatidylethanolamine LPE (20:1), phosphocholine PC (20:0/22:4), PI (18:1/18:2 and 20:0/18:2) (decreased). These findings suggest that increasing numbers of mTBI induce a range of changes dependent upon the lipid species, which likely reflect a balance of damage and reparative responses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. PD‐L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer.
- Author
-
Miller, Timothy J., Anyaegbu, Chidozie C., Lee‐Pullen, Tracey F., Spalding, Lisa J., Platell, Cameron F., and McCoy, Melanie J.
- Abstract
Background: The prognostic value of tumor‐associated dendritic cells (DC) in colon cancer remains poorly understood. This may be in part due to the interchangeable expression of immunostimulatory and immunoinhibitory molecules on DC. Here we investigated the prognostic impact of CD11c+ DC co–expressing the immunoinhibitory molecule PD‐L1 and their spatial relationship with CD8+ T‐cells in patients treated for stage III colon cancer. Methods: Tissue microarrays containing representative cores of central tumor, leading edge, and adjacent normal tissue from 221 patients with stage III colon cancer were immunostained for CD8, CD11c, PD‐L1, and cytokeratin using immunofluorescent probes. Cells were quantified using StrataQuest digital image analysis software, with intratumoral and stromal regions analyzed separately. Kaplan‐Meier estimates and Cox regression were used to assess survival. Results: Intratumoral CD8+ cell density (HR =.52, 95% confidence interval [CI].33‐.83, P =.007), stromal CD11c+ cell density (HR =.52, 95% CI.33‐.83, P =.006), intratumoral CD11c+PD‐L1+ cell density (HR =.57, 95% CI.35‐.92, P =.021), and stromal CD11c+PD‐L1+ cell density (HR =.48, 95% CI.30‐.77, P =.003) on leading‐edge cores were all significantly associated with good survival. CD8+ cell density was positively correlated with both CD11c+ cell density and CD11c+PD‐L1+ cell density in tumor epithelium and stromal compartments. Conclusion: Here we showed that PD‐L1‐expressing DC in the tumor microenvironment are associated with improved survival in stage III colon cancer and likely reflect an immunologically "hot" tumor microenvironment. Further investigation into the expression of immunomodulatory molecules by tumor‐associated DC may help to further elucidate their prognostic value. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Optimisation of multiplex immunofluorescence for a non-spectral fluorescence scanning system.
- Author
-
Anyaegbu, Chidozie C., Lee-Pullen, Tracey F., Miller, Timothy J., Abel, Tamara N., Platell, Cameron F., and McCoy, Melanie J.
- Subjects
- *
SCANNING systems , *IMMUNOFLUORESCENCE , *FLUORESCENCE , *IMAGING systems , *MULTISPECTRAL imaging - Abstract
The use of multi-colour immunofluorescence (IF) for immunophenotyping in formalin-fixed paraffin-embedded tissue sections is gaining popularity worldwide. This technique allows for the simultaneous detection of multiple markers on the same tissue section, thereby yielding more complex information than is possible by chromogenic immunohistochemistry (IHC). However, many commercially-available multiplex IF kits are designed for use in conjunction with a multispectral imaging system, to which many research groups have limited access. Here we present two 5-colour IF panels designed for T cell characterisation in human colorectal tissue, which can be imaged using a non-spectral fluorescence slide scanner with standard band-pass filters. We describe the optimisation process and the key considerations in developing a multiplex fluorescence assay, and discuss some of the advantages and disadvantages of using multiplex IF with a non-spectral imaging system. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Immunohistochemical detection of PD-L1 for research studies: which antibody and what protocol?
- Author
-
Anyaegbu, Chidozie C., Garrett, Kerryn, Hemmings, Chris, Lee-Pullen, Tracey F., and McCoy, Melanie J.
- Published
- 2017
- Full Text
- View/download PDF
9. Chemotherapy Enhances Cross-Presentation of Nuclear Tumor Antigens.
- Author
-
Anyaegbu, Chidozie C., Lake, Richard A., Heel, Kathy, Robinson, Bruce W., and Fisher, Scott A.
- Subjects
- *
CANCER chemotherapy , *TUMOR antigens , *ANTIGEN presentation , *CHEMOPREVENTION , *ANTIGEN processing , *IMMUNE recognition , *CANCER treatment , *IMMUNOTHERAPY - Abstract
Cross-presentation of tumor antigen is essential for efficient priming of naïve CD8+ T lymphocytes and induction of effective anti-tumor immunity. We hypothesized that the subcellular location of a tumor antigen could affect the efficiency of cross-presentation, and hence the outcome of anti-tumor responses to that antigen. We compared cross-presentation of a nominal antigen expressed in the nuclear, secretory, or cytoplasmic compartments of B16 melanoma tumors. All tumors expressed similar levels of the antigen. The antigen was cross-presented from all compartments but when the concentration was low, nuclear antigen was less efficiently cross-presented than antigen from other cellular locations. The efficiency of cross-presentation of the nuclear antigen was improved following chemotherapy-induced tumor cell apoptosis and this correlated with an increase in the proportion of effector CTL. These data demonstrate that chemotherapy improves nuclear tumor antigen cross-presentation and could be important for anti-cancer immunotherapies that target nuclear antigens. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Simultaneous flow cytometric characterization of multiple cell types and metabolic states in the rat brain after repeated mild traumatic brain injury.
- Author
-
Anyaegbu, Chidozie C., Mao, Yilin, McGonigle, Terry, Raja, Sushmitha, Clarke, Thomas, Black, Anna M.B., Solomon, Tanya, Fuller, Kathy, and Fitzgerald, Melinda
- Subjects
- *
BRAIN injuries , *PROLIFERATING cell nuclear antigen , *FRACTALKINE , *CELL populations , *NITRIC-oxide synthases , *RATS - Abstract
• Simultaneous identification of 9 distinct cell populations in the rat brain. • Increased iNOS immunoreactivity in activated microglia after two repeated mild TBI. • Some metabolic markers vary in sensitivity to inter-cohort experimental differences. • Analyse markers sensitive to experimental differences in the same sampling cohort. Cellular responses at the sub-acute phase of mild traumatic brain injury (mTBI), and their contribution to ongoing damage, are unclear, complex and require simultaneous assessment of multiple cells to elucidate. An 11-colour flow cytometry method for analysing brain cells was evaluated in a weight-drop rat model of repeated mTBI. Animals received sham, one, two or three mTBI delivered at 24 h intervals (n = 6/group). Cerebrum homogenates were prepared 11 days after first mTBI, in two cohorts of n = 3/group to enable same-day staining of fresh tissue. Percentages of neurons, astrocytes, microglia, mature oligodendrocytes and NeuN + CC1+ cells, neutrophils, macrophages and non-myeloid leukocytes, and their immunoreactivity for cell damage indicators (inducible nitric oxide synthase; iNOS, proliferating cell nuclear antigen; PCNA, 8-Oxo-2′-deoxyguanosine; 8OHDG and 4-hydroxynonenal; HNE), were assessed. Median fluorescence intensity (MFI) of iNOS in activated microglia increased following two, but not one or three, mTBI (p = 0.04). However, there were differences between processing cohorts in terms of percentages and MFI of some PCNA+, iNOS+, 8OHDG + and HNE + cell populations. Previous applications of flow cytometry for rat brain analysis were typically limited to three or four markers. This method uses 11 markers to identify nine cell populations and evaluate their immunoreactivity to four metabolic indicators of cell damage. Flow cytometry can be useful for discerning injury-related changes in multiple rat brain cells. However, markers sensitive to subtle changes in experimental conditions must be identified in pilot experiments and subsequently analysed in the same tissue-processing cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. The Prognostic and Predictive Value of SOX2+ Cell Densities in Patients Treated for Colorectal Cancer.
- Author
-
Miller, Tim J., McCoy, Melanie J., Lee-Pullen, Tracey F., Anyaegbu, Chidozie C., Hemmings, Christine, Bulsara, Max K., and Platell, Cameron F.
- Subjects
CANCER patients ,COLON tumors ,COMBINED modality therapy ,FLUOROURACIL ,IMMUNOHISTOCHEMISTRY ,RECTUM tumors ,SURVIVAL ,TRANSCRIPTION factors ,TUMOR markers ,TUMOR classification ,CYTOMETRY ,OXALIPLATIN ,PROPORTIONAL hazards models ,DATA analysis software ,MICROARRAY technology ,KAPLAN-Meier estimator - Abstract
SOX2 (sex-determining region-Y homeobox-2) is a transcription factor essential for the maintenance of pluripotency and is also associated with stem-cell-like properties in preclinical cancer models. Our previous study on a cohort of stage III colon cancer patients demonstrated high SOX2
+ cell densities were associated with poor prognosis. However, most patients were treated with adjuvant chemotherapy so the prognostic value of SOX2 could not be assessed independently from its value as a predictive marker for non-response to chemotherapy. This study aimed to assess whether SOX2 was a true prognostic marker or a marker for chemotherapy response in a historical cohort of patients, a high proportion of whom were chemotherapy-naïve. SOX2 immunostaining was performed on tissue micro-arrays containing tumor cores from 797 patients with stage II and III colorectal cancer. SOX2+ cell densities were then quantified with StrataQuest digital image analysis software. Overall survival was assessed using Kaplan–Meier estimates and Cox regression. It was found that high SOX2+ cell densities were not associated with poor overall survival. Furthermore, all patients had a significant improvement in survival after 5-fluorouracil (5-FU) treatment, irrespective of their SOX2+ cell density. Therefore, SOX2+ cell densities were not associated with prognosis or chemotherapy benefit in this study. This is in contrast to our previous study, in which most patients received oxaliplatin as part of their treatment, in addition to 5-FU. This suggests SOX2 may predict response to oxaliplatin treatment, but not 5-FU. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. The Prognostic and Predictive Value of SOX2 + Cell Densities in Patients Treated for Colorectal Cancer.
- Author
-
Miller TJ, McCoy MJ, Lee-Pullen TF, Anyaegbu CC, Hemmings C, Bulsara MK, and Platell CF
- Abstract
SOX2 (sex-determining region-Y homeobox-2) is a transcription factor essential for the maintenance of pluripotency and is also associated with stem-cell-like properties in preclinical cancer models. Our previous study on a cohort of stage III colon cancer patients demonstrated high SOX2
+ cell densities were associated with poor prognosis. However, most patients were treated with adjuvant chemotherapy so the prognostic value of SOX2 could not be assessed independently from its value as a predictive marker for non-response to chemotherapy. This study aimed to assess whether SOX2 was a true prognostic marker or a marker for chemotherapy response in a historical cohort of patients, a high proportion of whom were chemotherapy-naïve. SOX2 immunostaining was performed on tissue micro-arrays containing tumor cores from 797 patients with stage II and III colorectal cancer. SOX2+ cell densities were then quantified with StrataQuest digital image analysis software. Overall survival was assessed using Kaplan-Meier estimates and Cox regression. It was found that high SOX2+ cell densities were not associated with poor overall survival. Furthermore, all patients had a significant improvement in survival after 5-fluorouracil (5-FU) treatment, irrespective of their SOX2+ cell density. Therefore, SOX2+ cell densities were not associated with prognosis or chemotherapy benefit in this study. This is in contrast to our previous study, in which most patients received oxaliplatin as part of their treatment, in addition to 5-FU. This suggests SOX2 may predict response to oxaliplatin treatment, but not 5-FU.- Published
- 2020
- Full Text
- View/download PDF
13. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.
- Author
-
McCoy MJ, Hemmings C, Anyaegbu CC, Austin SJ, Lee-Pullen TF, Miller TJ, Bulsara MK, Zeps N, Nowak AK, Lake RA, and Platell CF
- Subjects
- Aged, Chemoradiotherapy methods, Female, Humans, Kaplan-Meier Estimate, Lymphocyte Count, Lymphocytes, Tumor-Infiltrating metabolism, Male, Middle Aged, Neoadjuvant Therapy methods, Outcome Assessment, Health Care methods, Prognosis, Rectal Neoplasms metabolism, Rectal Neoplasms therapy, T-Lymphocytes, Regulatory metabolism, Lymphocytes, Tumor-Infiltrating immunology, Rectal Neoplasms immunology, T-Lymphocytes, Regulatory immunology
- Abstract
Neoadjuvant (preoperative) chemoradiotherapy (CRT) decreases the risk of rectal cancer recurrence and reduces tumour volume prior to surgery. However, response to CRT varies considerably between individuals and factors associated with response are poorly understood. Foxp3+ regulatory T cells (Tregs) inhibit anti-tumour immunity and may limit any response to chemotherapy and radiotherapy. We have previously reported that a low density of Tregs in the tumour stroma following neoadjuvant CRT for rectal cancer is associated with improved tumour regression. Here we have examined the association between Treg density in pre-treatment diagnostic biopsy specimens and treatment response, in this same patient cohort. We aimed to determine whether pre-treatment tumour-infiltrating Treg density predicts subsequent response to neoadjuvant CRT. Foxp3+, CD8+ and CD3+ cell densities in biopsy samples from 106 patients were assessed by standard immunohistochemistry (IHC) and evaluated for their association with tumour regression grade and survival. We found no association between the density of any T cell subset pre-treatment and clinical outcome, indicating that tumour-infiltrating Treg density does not predict response to neoadjuvant CRT in rectal cancer. Taken together with the findings of the previous study, these data suggest that in the context of neoadjuvant CRT for rectal cancer, the impact of chemotherapy and/or radiotherapy on anti-tumour immunity may be more important than the state of the pre-existing local immune response.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.